semaglutide loss of exclusivity Patent Expiry Day: Novo Nordisk India MD On How Company Plans To Defend Its Dominance The Heavy Price of GLP-1

Most studies did not report changes in waist circumference

This longer gap increases the risk of appetite return and weight regain, so most providers avoid it unless specifically indicated for side effect management

12,13 In this study, there was no significant reduction in body weight at 12 weeks in the treatment arm, which implies that the reduction in ICP was likely to have been mediated by a reduction in CSF secretion, the mechanism demonstrated in preclinical studies, rather than through weight loss

Funding information This study was funded by Novo Nordisk A/S

Particularly important if your food intake was limited before discovering the pregnancy

However, insiders predict that clinical testing will expand access in the next three to five years as obesity rates soar for children ages 6 to 11